Real-time Estimate
Other stock markets
|
5-day change | 1st Jan Change | ||
27 EUR | 0.00% |
|
-0.74% | -12.90% |
Summary
- Overall, the company has poor fundamentals for a medium to long-term investment strategy.
- From a short-term investment perspective, the company presents a deteriorated fundamental situation
Strengths
- The average target price set by analysts covering the stock is above current prices and offers a tremendous appreciation potential.
- The group usually releases upbeat results with huge surprise rates.
Weaknesses
- According to Standard & Poor's' forecast, revenue growth prospects are expected to be very low for the next fiscal years.
- One of the major weak points of the company is its financial situation.
- In relation to the value of its tangible assets, the company's valuation appears relatively high.
- The company is not the most generous with respect to shareholders' compensation.
Ratings chart - Surperformance
Chart ESG Refinitiv
Sector: Pharmaceuticals
1st Jan change | Capi. | Investor Rating | ESG Refinitiv | |
---|---|---|---|---|
-12.90% | 1.49B | B- | ||
+3.79% | 95.71B | A- | ||
+6.58% | 41.64B | A- | ||
-13.20% | 32.7B | B- | ||
+79.72% | 28.65B | A | ||
-16.02% | 15.38B | C | ||
-8.17% | 12.97B | B- | ||
-12.49% | 11.47B | D+ | ||
+162.44% | 9.92B | D | ||
-54.92% | 9.07B | B |
Financials
Valuation
Momentum
Consensus
Business Predictability
Environment
Governance
Controversy
Technical analysis
- Stock Market
- Equities
- BIO3 Stock
- Ratings Biotest AG